Climb Bio slips after early-stage trial data for kidney disease drug

Baird has increased its price target on Climb Bio (CLYM) stock to $25, up from $21, while keeping an Outperform rating. They highlight Phase 1 data for CLYM116, an anti-APRIL monoclonal antibody, demonstrating near-complete April suppression and decreased IgA and Gd-IgA1 in healthy volunteers. This profile is similar to earlier anti-APRILs but with a significantly longer half-life.

Baird anticipates initial Phase 2 data to be available in the first half of 2027, with plans to launch a Phase 3 trial in 2027. They have raised their probability of success to 50% for this concept. Climb Bio recently announced positive Phase 1 trial results for CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy, which showed substantial APRIL and IgA suppression, with a drug half-life of approximately 29 days.

This success has prompted H.C. Wainwright to also raise its price target for Climb Bio to $24, maintaining a Buy rating, and estimating a 30% chance of approval for CLYM116. Furthermore, Climb Bio has partnered with Beijing Mabworks Biotech to start a Phase 2 trial for IgA nephropathy in China, a significant step in their regional efforts.

H.C. Wainwright also reiterated a $20 price target and a Buy rating on Climb Bio after presenting clinical data on another drug, budoprutug, at a medical conference. These updates demonstrate ongoing progress and interest in Climb Bio's pipeline.